Ropack expands services with new plants; Compounder closes facility after FDA inspection;

> The FDA is warning providers not to use compounded drugs made by California's Park Compounding Pharmacy after an inspection found issues, leading to the voluntary closure of the facility while problems are resolved. Notice

> Lonza says it will create a scalable manufacturing process for Benitec Biopharma's gene-silencing technology. Report

> Canada's Ropack is rebranding as Ropack Pharma Solutions after buying two Forest Pharmaceutical plants that allow it to offer manufacturing operations in the U.S. Report

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.